Compare UXIN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | CMPS |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.3M | 598.7M |
| IPO Year | 2018 | 2020 |
| Metric | UXIN | CMPS |
|---|---|---|
| Price | $2.86 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.43 |
| AVG Volume (30 Days) | 83.2K | ★ 1.5M |
| Earning Date | 09-23-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $340,011,237.00 | N/A |
| Revenue This Year | $727.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 63.82 | N/A |
| 52 Week Low | $2.45 | $2.25 |
| 52 Week High | $5.41 | $7.09 |
| Indicator | UXIN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 55.64 |
| Support Level | $2.56 | $4.90 |
| Resistance Level | $3.08 | $5.57 |
| Average True Range (ATR) | 0.24 | 0.35 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 62.90 | 92.51 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.